FDA seeks more study data on wider use of Erbitux

Erbitux makers Eli Lilly and Co. and Bristol-Myers Squibb announced that the FDA postponed its approval decision on the drug's use to treat head and neck tumors. The application is separate from the companies' recently withdrawn request to promote Erbitux for nonsmall-cell lung cancer.

View Full Article in:

Indianapolis Star (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX